ACU-URO17 Bladder Cancer Test
Accurate, Cost Effective, Non-Invasive – FDA Designated “Breakthrough Device” Significant New Revenue Stream
> 95% Sensitivity, > 90% Specificity, 100% NPV, 91% PPV
Detects both high and low grade bladder cancer
Risk stratification tool for additional workup (i.e., Cystoscopy, UroVysion™ FISH)
- Acupath – first lab to offer nationwide (launched July 2019)
- Used in conjunction with urine cytology or as a stand-alone test
- Non-invasive, inexpensive, and paid in-network by most insurance plans
- FDA designated “Breakthrough Device”; CE Approved
- 100% NPV – provides confirmation of negative / benign urine cytology results
- Triages indeterminate (atypical / suspicious) cytology results and helps to rule in or out additional diagnostic procedures and tests
- Detects both low and high grade urothelial carcinoma
© 2024 Acupath Laboratories. All rights reserved